German benefit assessment hammers nail in Novartis' aliskiren coffin
This article was originally published in Scrip
Executive Summary
Novartis' antihypertensive Rasilamlo (aliskiren plus amlopidine) offers no proven benefit over comparators, says Germany's Institute for Quality and Eficinecy in Healthcare, IWQiG. The conclusion comes as no surprise. In September the firm stopped marketing the drug in Germany because it did not have the necessary data to make a successful submission under the early benefit assessment.